The global radioactive tracer market is primarily fueled by the rising global incidence of cancer, cardiovascular diseases, and neurological disorders, coupled with technological advancements in radiopharmaceuticals. Valued at USD 3.5 billion in 2025, the market is projected to reach USD 6.8 billion by 2033, growing at a CAGR of 8.9% during the forecast period.

The global radioactive tracer market is primarily fueled by the rising global incidence of cancer, cardiovascular diseases, and neurological disorders, coupled with technological advancements in radiopharmaceuticals. Valued at USD 3.5 billion in 2025, the market is projected to reach USD 6.8 billion by 2033, growing at a CAGR of 8.9% during the forecast period.